InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.02
(
0.08%
)
Bitcoin
62,862.96
(
-0.29%
)
Post# of 251777
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

lgonber

Send PM Follow Ignore
Followers 12
Posts 648
Boards Moderated 0
Alias Born 12/20/2014

lgonber

Re: lgonber post# 189330

Monday, 03/30/2015 11:11:46 AM

Monday, March 30, 2015 11:11:46 AM

Post# of 251777
in relation to that, look at todays aquisition of Auspex, wich went public in February 2014 at $12 per share, and today´s $101-per-share takeout is a huge and fast win for the company's shareholders. But Auspex has no approved products (its first drug will be filed later this year), so Teva is paying a big price for a company which does not have any product in the market!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up